Bristol-Myers Squibb Company
BMYBristol-Myers Squibb Company, doing business as Bristol Myers Squibb, is an American multinational pharmaceutical company headquartered in Princeton, New Jersey. The company's primary products are apixaban (Eliquis) for people with atrial fibrillation (30% of 2025 revenues); nivolumab (Opdivo), used to treat certain types of cancer (21% of 2025 revenues); lenalidomide (Revlimid), used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (6% of 2025 revenues); abatacept (Orencia), used to treat autoimmune diseases such as rheumatoid arthritis (8% of 2025 revenues); pomalidomide (Pomalyst/Imnovid), an anti-cancer medication used for the treatment of multiple myeloma and AIDS-related Kaposi sarcoma (6% of 2025 revenues); ipilimumab (Yervoy), to treat cancer (6% of 2025 revenues); and luspatercept (Reblozyl) for the treatment of anemia in beta thalassemia and myelodysplastic syndromes (5% of 2025 revenues). In 2025, 69% of the company's revenues came from the United States.
Drugs in Pipeline
113
Phase 3 Programs
51
Upcoming Catalysts
11
Next Catalyst
This month
Market Overview
Stock performance and key metrics
11 upcoming, 0 past
Nivolumab Phase 2 Est. Readout
Estimated primary completion for Nivolumab trial (NCT05502315) in Castration-resistant Prostate Cancer. Topline data typically follows completion by weeks to months.
SourceMilvexian Phase 3 Est. Readout
Estimated primary completion for Milvexian trial (NCT05702034) in Ischemic Stroke; Ischemic Attack, Transient. Topline data typically follows completion by weeks to months.
Source9 more catalysts beyond 14 days
Start a 48-hour free trial to see all upcoming catalysts
How BMY's past catalysts played out
Relatlimab
Lymphoma, Non-Hodgkin
Vinflunine
Bladder Cancer
BMS-936558 (Nivolumab)
Melanoma
DCV/ASV/BMS-791325
Hepatitis C
adefovir
Hepatitis B
BMS-986489 (BMS-986012+Nivolumab)
Extensive-Stage Small Cell Lung Cancer
Ozanimod
Colitis, Ulcerative
Irbesartan
Congestive Heart Failure
Deucravacitinib
Plaque Psoriasis
stavudine extended-release, lamivudine, efavirenz
HIV Infections
paclitaxel (PTX)
Breast Cancer
BMS-790052 (Daclatasvir)
Hepatitis C
Entecavir (ETV)
Hepatitis B
NKTR-214
Melanoma
Intravenous (IV) abatacept
Rheumatoid Arthritis
Indinavir sulfate
HIV Infections
Repotrectinib
Carcinoma, Non-Small-Cell Lung
Tanespimycin
Multiple Myeloma
Apremilast
Psoriasis
Muraglitazar
Diabetes Mellitus
BMS-986165
Ulcerative Colitis
KarXT
Bipolar-I Disorder With Mania or Mania With Mixed Features
Abatacept
Nephrotic Syndrome
Belatacept
Kidney Transplantation
mavacamten
Hypertrophic Cardiomyopathy
BMS-986504
Pancreatic Ductal Adenocarcinoma
Pumitamig
Untreated, Unresectable, or Metastatic Colorectal Cancer
Entecavir
Chronic Hepatitis B
Peginterferon Lambda-1a
Hepatitis C Virus
Cetuximab/Erbitux
Head and Neck Cancer
Apixaban
Deep-Vein Thrombosis
Megestrol acetate
Anorexia
Iza-bren
Non-Small Cell Lung Cancer
Lenalidomide
Lymphoma
Daclatasvir
Hepatitis C
Xanomeline and Trospium Chloride Capsules
Schizophrenia
Sofosbuvir
Hepatitis C
SAR302503
Hematopoietic Neoplasm
Asunaprevir
Hepatitis C Virus Infection
BMS-986205
Advanced Cancer
KarX-EC
Alzheimer Disease
brivanib
Advanced Non-small Cell Lung Cancer
BMS-986278
Pulmonary Fibrosis
Nivolumab/rHuPH20
Melanoma
Stavudine
AIDS Dementia Complex
Nivolumab and rHuPH20
Clear Cell Renal Cell Carcinoma
Nivolumab 3 mg/kg IV
Melanoma
Milvexian
Ischemic Stroke; Ischemic Attack, Transient
Ipilimumab
Prostatic Neoplasms, Castration-Resistant
BMS-986393
Relapsed or Refractory Multiple Myeloma (RRMM)
Nivolumab
Recurrent Head and Neck Squamous Cell Carcinoma
Ticagrelor
Coronary Artery Disease
Procarbazine
Lymphoma
ipilimumab (MDX-010, BMS-734016)
Melanoma
peg-interferon alfa-2a
Hepatitis C Virus
Oral Azacitidine
Acute Myeloid Leukemia
Pomalidomide
Multiple Myeloma
HNO Donor
Heart Failure
Cobimetinib
Advanced or Metastatic Solid Tumors
BMS-986207
Non-Small Cell Lung Cancer
BMS-582949
Rheumatoid Arthritis, NOS
BMS-986166
Dermatitis, Atopic
BMS-823778
Diabetes Mellitus, Type 2
CC-97540
Lupus Erythematosus, Systemic
Pexacerfont
Major Depressive Disorder
cabiralizumab
Peripheral T Cell Lymphoma
Combination of varlilumab and nivolumab
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Nivolumab & Ipilimumab
Prostate Cancer
BMS-986016
Hematologic Neoplasms
Nivolumab Monotherapy
Advanced Metastatic Cancer
Ipilimumab, Melphalan and Dactinomycin
Melanoma
Nivolumab/Ipilimumab
Carcinoma, Renal Cell
COM701 in combination with BMS-986207 and nivolumab.
Endometrial Neoplasms
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination
Cutaneous Squamous Cell Carcinoma
Nivolumab 240 MG
Gastroesophageal Adenocarcinoma
Nivolumab 480mg + Ipilimumab
Colorectal Cancer Metastatic
Platinum Doublet Chemotherapy
Non-Small-Cell Lung Cancer
Lirilumab
CANCER,NOS
peginterferon alfa-2a
Hepatitis C Virus
Ixabepilone
Breast Cancer
BMS-650032
Chronic Hepatitis C
BMS-986408
Advanced Solid Tumors
BMS-986036
Hepatic Cirrhosis
Anti-IP-10 Antibody
Colitis, Ulcerative
MDX-010
Prostate Cancer
BMS-986179
Malignant Solid Tumor
Nivolumab (BMS-936558)
Melanoma
BMS-986177
Acute Ischemic Stroke
Nivolumab + Relatlimab
Melanoma Stage III
MDX-1100
Ulcerative Colitis
Arlocabtagene Autoleucel
Multiple Myeloma
BMS-790052
Hepatitis C Infection
Luspatercept
Anemia
BMS-986178
Advanced Cancer
relatlimab+nivolumab
Melanoma
MDX-060
Hodgkin's Disease
BMS-986213
Gastric Cancer
Elotuzumab (BMS-901608; HuLuc63)
Smoldering Multiple Myeloma
BMS-770767
Dyslipidemia
Elotuzumab
Multiple Myeloma
BMS-817399
Rheumatoid Arthritis
Nivolumab 40 mg in 4 ml Injection
Uterine Cervical Neoplasms
CTLA4Ig / Abatacept
Psoriasis Vulgaris
Tyrosinase/gp100/MART-1 Peptides
Intraocular Melanoma
BMS-954561
Post-Herpetic Neuralgia (PHN)
Cabazitaxel
Metastatic Prostate Neuroendocrine Carcinoma
Trametinib
Colorectal Cancer
BMS-791325
Chronic Hepatitis C
BMS-931699
Lupus
BMS-741672
Neuropathic Pain
rHuPH20
Neoplasms by Site
BMS-986158
Advanced Tumors
BMS-690514
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Relatlimab | Phase 3 | Lymphoma, Non-Hodgkin | - | - |
Vinflunine | Phase 3 | Bladder Cancer | - | - |
BMS-936558 (Nivolumab) | Phase 3 | Melanoma | - | - |
DCV/ASV/BMS-791325 | Phase 3 | Hepatitis C | - | - |
adefovir | Phase 3 | Hepatitis B | - | - |
BMS-986489 (BMS-986012+Nivolumab) | Phase 3 | Extensive-Stage Small Cell Lung Cancer | - | - |
Ozanimod | Phase 3 | Colitis, Ulcerative | - | - |
Irbesartan | Phase 3 | Congestive Heart Failure | - | - |
Deucravacitinib | Phase 3 | Plaque Psoriasis | - | - |
stavudine extended-release, lamivudine, efavirenz | Phase 3 | HIV Infections | - | - |
paclitaxel (PTX) | Phase 3 | Breast Cancer | - | - |
BMS-790052 (Daclatasvir) | Phase 3 | Hepatitis C | - | - |
Entecavir (ETV) | Phase 3 | Hepatitis B | - | - |
NKTR-214 | Phase 3 | Melanoma | - | - |
Intravenous (IV) abatacept | Phase 3 | Rheumatoid Arthritis | - | - |
Indinavir sulfate | Phase 3 | HIV Infections | - | - |
Repotrectinib | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Tanespimycin | Phase 3 | Multiple Myeloma | - | - |
Apremilast | Phase 3 | Psoriasis | - | - |
Muraglitazar | Phase 3 | Diabetes Mellitus | - | - |
BMS-986165 | Phase 3 | Ulcerative Colitis | - | - |
KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | - | - |
Abatacept | Phase 3 | Nephrotic Syndrome | - | - |
Belatacept | Phase 3 | Kidney Transplantation | - | - |
mavacamten | Phase 3 | Hypertrophic Cardiomyopathy | - | - |
BMS-986504 | Phase 3 | Pancreatic Ductal Adenocarcinoma | - | - |
Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | - | - |
Entecavir | Phase 3 | Chronic Hepatitis B | - | - |
Peginterferon Lambda-1a | Phase 3 | Hepatitis C Virus | - | - |
Cetuximab/Erbitux | Phase 3 | Head and Neck Cancer | - | - |
Apixaban | Phase 3 | Deep-Vein Thrombosis | - | - |
Megestrol acetate | Phase 3 | Anorexia | - | - |
Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | - | - |
Lenalidomide | Phase 3 | Lymphoma | - | - |
Daclatasvir | Phase 3 | Hepatitis C | - | - |
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
Sofosbuvir | Phase 3 | Hepatitis C | - | - |
SAR302503 | Phase 3 | Hematopoietic Neoplasm | - | - |
Asunaprevir | Phase 3 | Hepatitis C Virus Infection | - | - |
BMS-986205 | Phase 3 | Advanced Cancer | - | - |
KarX-EC | Phase 3 | Alzheimer Disease | - | - |
brivanib | Phase 3 | Advanced Non-small Cell Lung Cancer | - | - |
BMS-986278 | Phase 3 | Pulmonary Fibrosis | - | - |
Nivolumab/rHuPH20 | Phase 3 | Melanoma | - | - |
Stavudine | Phase 3 | AIDS Dementia Complex | - | - |
Nivolumab and rHuPH20 | Phase 3 | Clear Cell Renal Cell Carcinoma | - | - |
Nivolumab 3 mg/kg IV | Phase 3 | Melanoma | - | - |
Milvexian | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | - | - |
Ipilimumab | Phase 3 | Prostatic Neoplasms, Castration-Resistant | - | - |
BMS-986393 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | - | - |
Nivolumab | Phase 3 | Recurrent Head and Neck Squamous Cell Carcinoma | - | - |
Ticagrelor | Phase 2 | Coronary Artery Disease | - | - |
Procarbazine | Phase 2 | Lymphoma | - | - |
ipilimumab (MDX-010, BMS-734016) | Phase 2 | Melanoma | - | - |
peg-interferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Oral Azacitidine | Phase 2 | Acute Myeloid Leukemia | - | - |
Pomalidomide | Phase 2 | Multiple Myeloma | - | - |
HNO Donor | Phase 2 | Heart Failure | - | - |
Cobimetinib | Phase 2 | Advanced or Metastatic Solid Tumors | - | - |
BMS-986207 | Phase 2 | Non-Small Cell Lung Cancer | - | - |
BMS-582949 | Phase 2 | Rheumatoid Arthritis, NOS | - | - |
BMS-986166 | Phase 2 | Dermatitis, Atopic | - | - |
BMS-823778 | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
CC-97540 | Phase 2 | Lupus Erythematosus, Systemic | - | - |
Pexacerfont | Phase 2 | Major Depressive Disorder | - | - |
cabiralizumab | Phase 2 | Peripheral T Cell Lymphoma | - | - |
Combination of varlilumab and nivolumab | Phase 2 | Squamous Cell Carcinoma of the Head and Neck (SCCHN) | - | - |
Nivolumab & Ipilimumab | Phase 2 | Prostate Cancer | - | - |
BMS-986016 | Phase 2 | Hematologic Neoplasms | - | - |
Nivolumab Monotherapy | Phase 2 | Advanced Metastatic Cancer | - | - |
Ipilimumab, Melphalan and Dactinomycin | Phase 2 | Melanoma | - | - |
Nivolumab/Ipilimumab | Phase 2 | Carcinoma, Renal Cell | - | - |
COM701 in combination with BMS-986207 and nivolumab. | Phase 2 | Endometrial Neoplasms | - | - |
Nivolumab 240 mg / Relatlimab 80 mg in a fixed dose combination | Phase 2 | Cutaneous Squamous Cell Carcinoma | - | - |
Nivolumab 240 MG | Phase 2 | Gastroesophageal Adenocarcinoma | - | - |
Nivolumab 480mg + Ipilimumab | Phase 2 | Colorectal Cancer Metastatic | - | - |
Platinum Doublet Chemotherapy | Phase 2 | Non-Small-Cell Lung Cancer | - | - |
Lirilumab | Phase 2 | CANCER,NOS | - | - |
peginterferon alfa-2a | Phase 2 | Hepatitis C Virus | - | - |
Ixabepilone | Phase 2 | Breast Cancer | - | - |
BMS-650032 | Phase 2 | Chronic Hepatitis C | - | - |
BMS-986408 | Phase 2 | Advanced Solid Tumors | - | - |
BMS-986036 | Phase 2 | Hepatic Cirrhosis | - | - |
Anti-IP-10 Antibody | Phase 2 | Colitis, Ulcerative | - | - |
MDX-010 | Phase 2 | Prostate Cancer | - | - |
BMS-986179 | Phase 2 | Malignant Solid Tumor | - | - |
Nivolumab (BMS-936558) | Phase 2 | Melanoma | - | - |
BMS-986177 | Phase 2 | Acute Ischemic Stroke | - | - |
Nivolumab + Relatlimab | Phase 2 | Melanoma Stage III | - | - |
MDX-1100 | Phase 2 | Ulcerative Colitis | - | - |
Arlocabtagene Autoleucel | Phase 2 | Multiple Myeloma | - | - |
BMS-790052 | Phase 2 | Hepatitis C Infection | - | - |
Luspatercept | Phase 2 | Anemia | - | - |
BMS-986178 | Phase 2 | Advanced Cancer | - | - |
relatlimab+nivolumab | Phase 2 | Melanoma | - | - |
MDX-060 | Phase 2 | Hodgkin's Disease | - | - |
BMS-986213 | Phase 2 | Gastric Cancer | - | - |
Elotuzumab (BMS-901608; HuLuc63) | Phase 2 | Smoldering Multiple Myeloma | - | - |
BMS-770767 | Phase 2 | Dyslipidemia | - | - |
Elotuzumab | Phase 2 | Multiple Myeloma | - | - |
BMS-817399 | Phase 2 | Rheumatoid Arthritis | - | - |
Nivolumab 40 mg in 4 ml Injection | Phase 2 | Uterine Cervical Neoplasms | - | - |
CTLA4Ig / Abatacept | Phase 2 | Psoriasis Vulgaris | - | - |
Tyrosinase/gp100/MART-1 Peptides | Phase 2 | Intraocular Melanoma | - | - |
BMS-954561 | Phase 2 | Post-Herpetic Neuralgia (PHN) | - | - |
Cabazitaxel | Phase 2 | Metastatic Prostate Neuroendocrine Carcinoma | - | - |
Trametinib | Phase 2 | Colorectal Cancer | - | - |
BMS-791325 | Phase 2 | Chronic Hepatitis C | - | - |
BMS-931699 | Phase 2 | Lupus | - | - |
BMS-741672 | Phase 2 | Neuropathic Pain | - | - |
rHuPH20 | Phase 2 | Neoplasms by Site | - | - |
BMS-986158 | Phase 2 | Advanced Tumors | - | - |
BMS-690514 | Phase 2 | Breast Cancer | - | - |
multiple myeloma
4 drugs in this indication
Alzheimer's
1 drug in this indication
Lupus Erythematosus, Systemic
1 drug in this indication
advanced melanoma
1 drug in this indication
blood cancer
1 drug in this indication
Duchenne muscular dystrophy
1 drug in this indication
multiple myeloma (relapsed or refractory)
1 drug in this indication
relapsed/refractory multiple myeloma
1 drug in this indication
Alzheimer's psychosis
1 drug in this indication
advanced hepatocellular carcinoma
1 drug in this indication
cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Bristol-Myers Squibb Company's drug pipeline?→
CatalystAlert tracks 113 drug candidates in Bristol-Myers Squibb Company's (BMY) pipeline across Phase 3, Phase 2. Its lead program is Relatlimab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Bristol-Myers Squibb Company's next FDA catalyst?→
Bristol-Myers Squibb Company's (BMY) next tracked catalyst is a Phase 2 expected October 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BMY biotech catalysts?→
Add BMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Bristol-Myers Squibb Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.